SavedAdd your journal

Journals / Güncel Retina Dergisi / 2018 / Cilt: 2 - Sayı: 4

Use of Anti-VEGF Agents and Lasers in Behçet’s Disease

Behçet Hastalığında Anti-VEGF ve Lazer Kullanımı

Sibel KADAYIFÇILAR
Pages
376–379
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In Behçet’s Disease laser treatment is indispensable in the management of complications like secondary glaucoma, secondary cataract, retinal tears and retinal NV.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Ocular form of Behçet’s Disease may end up in several complications.
📊
Key Findings & Data:Bevacizumab is reported to be effective for CME in some studies, however there are also articles reporting that it does not provide significant anatomic or functional benefit.
💡
Conclusion & Impact:In Behçet’s Disease laser treatment is indispensable in the management of complications like secondary glaucoma, secondary cataract, retinal tears and retinal NV.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Ocular form of Behçet’s Disease may end up in several complications. Anti-vasculoendothelial (anti-VEGF) agents and/or laser treatment are used in the management of these complications. Intravitreal Anti-VEGF agents are employed in Behçet’s Disease for the management of cystoid macular edema (CME) and neovascularization (NV). Bevacizumab is reported to be effective for CME in some studies, however there are also articles reporting that it does not provide significant anatomic or functional benefit. In Behçet’s Disease laser treatment is indispensable in the management of complications like secondary glaucoma, secondary cataract, retinal tears and retinal NV.

Özet

Behçet Hastalığının oküler tutulumu çeşitli komplikasyonlara yol açabilmektedir. Bu komplikasyonların yönetiminde antivasküloendotelyal büyüme faktörü (anti-VEGF) ajanlar ve/veya lazer tedavisi de kullanılmaktadır. Behçet Hastalığında intravitreal anti-VEGF ajanların başlıca uygulama alanları kistoid makula ödemi (KMÖ) ve neovaskülarizasyonlardır (NV). KMÖ için bevacizumabın etkin olduğunu bildiren yayınların yanı sıra anatomik ya da fonksiyonel fayda sağlamadığını bildiren yayınlar da mevcuttur. Behçet Hastalığında sekonder glokom, sekonder katarakt, retinal yırtık ve retinal NV gibi komplikasyonların tedavisinde lazer uygulamaları vazgeçilmez yere sahiptir.

🔖

Cite This Article

KADAYIFÇILAR, S. (2018). Use of Anti-VEGF Agents and Lasers in Behçet’s Disease. Güncel Retina Dergisi, Cilt: 2 - Sayı: 4, 376–379. https://ajindex.com/articles/178154

References (12)

  1. Kadayıfçılar S, Retina Hastalıklarında Anti-VEGF Tedaviler. Ret-Vit 2014;22(sp):104-116.
  2. Erdurman FC, Durukan AH, Mumcuoğlu T, Hürmeriç V. Intravitreal bevacizumab treatment of macular edema due to optic disc vasculitis. Ocul Immunol Inflamm 2009;17(1):56-58.
  3. Bae JH, Lee CS, Lee SC. Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Retina 2011;31(1):111-118.
  4. Mirshahi A, Namavari A, Djalilian A, Moharamzad Y, Chams H. Intravitreal bevacizumab (Avastin) for the treatment of cystoid macular edema in Behçet’s disease. Ocul Immunol Inflamm 2009;17(1):59-64.
  5. Ghassemi F, Afshari Mirak C, Chams H, Sabour S, Nilli Ahmadabadi M, Davatchi F, et al. Characteristics of macular edema in Behcet Disease after intravitreal bevacizumab injection. J Ophthalmic Vis Res 2017;12(1):44-52.
  6. Yüksekkaya P, Özdal P, Teke MY, Öztürk F. Behçet Hastalığına bağlı gelişen koroidal neovasküler membran. Ret-vit 2010;18(2):170-173.
  7. Toro M, Reibaldi M, Stella S, Amato R, Longo A, Gagliano C. Persistent macular edema with secondary choroidal neovascular membrane following a panuveitis in woman with Behçet’s disase resolved by a switching to aflibercept injections. Acta Ophthalmologica 2013;91(s):252 Georgopoulos M, Polak K, Prager F, Prünte C, Schmidt-Erfurth U. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 2009;93(4):457-462.
  8. Bae JH, Lee SC. Bilateral intraocular inflammation after intravitreal bevacizumab in Behcet’s disease. Eye 2010;24(4):735. Nussenblatt, Whitcup SM, Palestine AG. Role of Surgery in the Patient with Uveitis. In: Uveitis and Clinical Practice. 2nd edition. St Louis, Missouri. Mosby-Year Book, Inc 1996;145-150.
  9. Elgin U, Berker N, Batman A, Soykan E. Nd:YAG laser iridotomy in the management of secondary glaucoma associated with Behçet’s disease. Eur J Ophthalmol 2007;17(2):191-195.
  10. Kadayıfçılar S, Gedik S, Eldem B, İrkeç M. Cataract surgery in patients with Behçet’s disease. J Cataract Refract Surg. 2002;28(2):316-320.
  11. Süllü Y, Öğe İ, Erkan D. The result of cataract extraction and intraocular lens implantation in patients with Behçet’s disease. Acta Ophthalmol Scand 2000;78(6):680-683.
  12. Alfawaz A, Alsashidi S, Kalantan H, Al-Mezaine H, Abu AM. Cataract surgery under systemic infliximab therapy in patients with refractory uveitis associated with Behcet ddisease. Ann Saudi Med 20